Paper Review Records
All Paper Review Records
23 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
125
days
Exploration of Extravascular Tissue and Synovial Fluid Distribution of Extended Half-Life Factor IX Concentrates by Physiologically Based Pharmacokinetic Modelling
Authors
Sjoerd F. Koopman; Erik Sjögren; Peter J. Lenting; Marjon H. Cnossen; Ron A. A. MathôtShow moreShow less
Affiliations
1. Hospital Pharmacy-Clinical Pharmacology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands; 2. Department of Pharmaceutical Biosciences, Translational Drug Discovery and Development, Uppsala University, Uppsala, Sweden; 3. Pharmetheus, Uppsala, Sweden; 4. Université Paris-Saclay, Institut National de la Santé et de la Recherce Médicale (Inserm), Hémostase Inflammation Thrombose HITh U1176, Le Kremlin-Bicêtre, France; 5. Department of Pediatric Hematology and Oncology, Erasmus MC Sophia Children’s Hospital, University Medical Center Rotterdam, Rotterdam, The NetherlandsShow moreShow less
251
days
Once-Weekly Insulin Icodec: A Review of its Pharmacokinetic and Pharmacodynamic Properties
Authors
T. Heise; M. P. Haridas; N. R. Kristensen; C. Mathieu; R. Ribel-Madsen; T. R. PieberShow moreShow less
Affiliations
1. Profil, Neuss, Germany; 2. Novo Nordisk, Bangalore, India; 3. Novo Nordisk, Søborg, Denmark; 4. Clinical and Experimental Endocrinology, Katholieke Universiteit Leuven, Leuven, Belgium; 5. Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, AustriaShow moreShow less
144
days
The Predictive Value of Gastrin for the Absorption of Erlotinib in Patients with Non-Small Cell Lung Cancer
Authors
Niels Heersche; Daan A. C. Lanser; Sophie M. Ernst; Cornelis Kramers; Marthe S. Paats; Anne-Marie C. Dingemans; Ron H. N. van Schaik; Ron H. J. Mathijssen; G. D. Marijn VeermanShow moreShow less
Affiliations
1. Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands; 2. Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands; 3. Department of Pulmonology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands; 4. Department of Pharmacology-Toxicology and Internal Medicine, Radboud University Medical Center, Nijmegen, The NetherlandsShow moreShow less
233
days
Population Pharmacokinetic/Pharmacodynamic Analysis of HHT120, a Novel Direct Thrombin Inhibitor, in Healthy Participants from a Phase I Clinical Trial
Authors
Qingyu Yao; Xue Zhou; Yaou Liu; Jingyi Feng; Ran Xie; Runfeng Lin; Yongxing Wang; Qin Huang; Ying ZhouShow moreShow less
Affiliations
1. Clinical Trial Center, Beijing Key Laboratory of Clinical Pharmacology and Translation of Innovative Drugs, Peking University First Hospital, Beijing, China; 2. Livzon Pharmaceutical Group Co., Ltd., Zhuhai, China; 3. Department of Pharmacy, Peking University First Hospital, Beijing, China; 4. Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, ChinaShow moreShow less
244
days
The Variability in the Pharmacokinetics of Follitropin Alfa: A Systematic Review
Authors
Ranita Kirubakaran; Toni J. F. Michael; Beverley J. Vollenhoven; Vinayak Smith; Sophie L. StockerShow moreShow less
Affiliations
1. Department of Pharmacy, Seberang Jaya Hospital, Penang, Malaysia; 2. School of Clinical medicine, St. Vincent’s Healthcare Clinical Campus, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia; 3. School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; 4. Department of Obstetrics and Gynaecology, Monash University, Melbourne, Australia; 5. Monash IVF, Melbourne, Australia; 6. Women’s and Newborn Program, Monash Health, Melbourne, Australia; 7. Virtus Health Pty Ltd, Melbourne, Australia; 8. Department of Clinical Pharmacology and Toxicology, St. Vincent’s Hospital, Sydney, AustraliaShow moreShow less
331
days
A Patient-Centered Approach for Drug–Drug Interaction (DDI) Assessment: Integrating Nested Clinical DDI Studies to Verify Translatability of Healthy Volunteer DDI Data, Minimize Stand-Alone Trials, and Enrich Drug Labeling
Authors
Cheuk Fung Chan; Young Sun Scaringella; Fenglei HuangShow moreShow less
Affiliations
1. Clinical Pharmacology and Non-Clinical Safety Sciences, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, USAShow moreShow less
FAQ
How long does CLINICAL PHARMACOKINETICS take to review a manuscript?
As of 2026-11-18, CrushSCI has 23 complete review records for CLINICAL PHARMACOKINETICS. The fastest paper went from submission to acceptance in 57 days (How Feasible is the Use of Saliva for Antiviral Therapeutic Drug Monitoring? A Systematic Review and Analysis, received 2026-04-21, accepted 2026-06-17); the slowest took 331 days. The average is 151.8 days and the median is 130 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
